STOCK TITAN

Veracyte Stock Price, News & Analysis

VCYT Nasdaq

Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.

Veracyte, Inc. (Nasdaq: VCYT) is a global cancer diagnostics and genomic testing company whose news flow centers on clinical evidence, test performance, and financial results. The company describes its mission as transforming cancer care by empowering clinicians with high-value insights at key decision points in diagnosis and treatment. Its Veracyte Diagnostics Platform underpins tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, along with research tools like Afirma GRID and Decipher GRID.

On this page, readers can follow Veracyte news related to quarterly and annual financial results, including revenue and testing volume updates the company announces in earnings press releases and accompanying conference calls. Veracyte’s communications also highlight non-GAAP measures such as adjusted EBITDA and adjusted EBITDA margin, along with explanations of how these metrics are used internally and how they differ from GAAP figures.

Another major category of news involves clinical and scientific developments. Veracyte regularly reports on studies and abstracts that use its Afirma GRID and Decipher GRID platforms to develop and evaluate molecular signatures in thyroid and prostate cancer. Examples include publications on Afirma GRID-derived signatures to differentiate thyroid cancer risk groups and prospective validation data for biomarkers such as the PAM50 molecular signature in recurrent prostate cancer.

Investors and clinicians can also find announcements about Veracyte’s participation in healthcare and investor conferences, where management presents updates on the company’s diagnostics portfolio, research programs, and financial outlook. For ongoing insight into how Veracyte’s genomic tests and research tools are being used in practice and studied in trials, this news feed aggregates the company’s press releases and related updates in one place.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.1%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags

FAQ

What is the current stock price of Veracyte (VCYT)?

The current stock price of Veracyte (VCYT) is $31.09 as of April 10, 2026.

What is the market cap of Veracyte (VCYT)?

The market cap of Veracyte (VCYT) is approximately 2.5B.